Answers are grounded in this paper and cite their sources.
To our knowledge, this is the first reported study exploring duloxetine pharmacokinetics PBS. This trial found that the bariatric surgery group was exposed to only 57.7% of duloxetine as compared to the nonsurgery group. This finding suggests that clinicians need to monitor patients closely after bariatric surgery and that further exploration of the effects of bariatric surgery on antidepressant pharmacokinetic parameters is warranted.
No takes yet. Share an insight, caveat, or question.
Roerig et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: